Bcl-Y - specific antibodies

• US 5,672,686 A
• Filed: 10/11/1994
• Issued: 09/30/1997
• Est. Priority Date: 08/09/1994
• Status: Expired due to Term

• Current Assignee: Apoptosis Technology, Inc.
• Original Assignee: ImmunoGen Incorporated (Abbvie Incorporated)
• Inventors: Chittenden, Thomas D.
• Primary Examiner(s): Hutzell, Paula K.
• Assistant Examiner(s): Johnson, Nancy A.
• Application Number:
  US08/321,071
• Time in Patent Office: 1,085 Days
• Field of Search: 424/13.1, 424/139.1, 424/141.1, 424/178.1, 424/1.49, 435/188, 435/240.27, 530/387.1, 530/387.2, 530/387.9, 530/388.1, 530/388.2, 530/389.1, 530/391.3
• US Class Current: 530/387.9
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/4702 Regulators; Modulating activity

Abstract

The present invention is directed to an isolated Bcl-Y protein, nucleotide sequences coding for and regulating expression of the protein, antibodies directed against the protein, and recombinant vectors and host cells containing the genetic sequences coding for and regulating the expression of the protein sequence. The invention is also directed to genomic DNA, cDNA, and RNA encoding the Bcl-Y protein sequence and to corresponding antisense RNA sequences. Antibodies can be used to detect Bcl-Y in biological specimens, including, for example, human tissue samples. The present invention is further directed to methods of treating degenerative disorders characterized in inappropriate cell proliferation or inappropriate cell death. The present invention is further directed to methods for diagnosing degenerative disorders characterized in inappropriate cell proliferation or inappropriate cell death, as well as methods for monitoring the progress of such degenerative disorders.

Claims

1. An antibody capable of binding to a protein having the amino acid sequence as shown in FIG. 4, SEQ ID NO:

16, wherein said protein is human Bcl-Y protein.

3. The antibody of claims 1 or 2, wherein said antibody is selected from the group consisting of a polyclonal antibody and a monoclonal antibody.

4. The antibody of claim 3, wherein said antibody is a monoclonal antibody.

5. The antibody of claims 3 or 4, wherein said antibody is detectably labelled.

6. The antibody of claim 5, wherein said antibody is detectably labeled with a detectable label selected from the group consisting of a radiolabel, an enzyme label, a co-factor label, a fluorescent label, a paramagnetic label, a chemiluminescent label and a metal label.

2. An antibody capable of binding to a protein encoded by the nucleotide sequence as shown in FIG. 4, SEQ ID NO:

17, wherein said protein is human Bcl-Y protein.